Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial
AIMS: The phase 3 ECHO trial demonstrated superior progression-free survival (PFS) with acalabrutinib plus bendamustine-rituximab (BR) versus placebo plus BR in treatment-naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP-5862 (active metabolite) when administered with BR and evaluates exposure-response (efficacy/safety) relationships based on ECHO data. METHODS: In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP-5862 from ECHO plus 10 clinical trials. Exposure-response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO. RESULTS: Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP-5862 exposure. No impact of co-administration with BR was observed on PK exposure. Exposure-efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP-5862 exposure and PFS and BOR. Exposure-safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP-5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications). CONCLUSION: This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well-tolerated and efficacious in treatment of patients with TN MCL.
Authors
- Diansong Zhou (ORCID: https://orcid.org/0000-0002-2673-1069)
- Shringi Sharma (ORCID: https://orcid.org/0000-0002-3120-225X)
- Damilola Olabode (ORCID: https://orcid.org/0000-0001-7675-5707)
- Karthick Vishwanathan (ORCID: https://orcid.org/0000-0002-6555-8131)
- Simon A. Rule (ORCID: https://orcid.org/0000-0001-8937-6351)
- Roser Calvo (ORCID: https://orcid.org/0000-0001-6217-846X)
- Jincheng Yang (ORCID: https://orcid.org/0000-0002-4813-1056)
- Nurahamid Siddiki
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1002/bcp.70912
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00